Erica DiNapoli

Erica DiNapoli is an Assistant Editor for OncLive®. She joined the company in 2020 and now assists in editing and publishing both videos and informational articles to the website; she also helps manage the social media platforms. Prior to joining MJH Life Sciences, she was a student at Monmouth University and held two marketing internships at United Teletech Financial Federal Credit Union and Trendsetter Media & Marketing.

Articles

Interim REFLECT Analysis Reconfirms Efficacy, Safety of Rituximab Biosimilar in DLBCL

August 7th 2020

Manfred Welslau, MD, discusses findings from the REFLECT interim analysis that reconfirmed the activity of the rituximab biosimilar SDZ-RTX, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with diffuse large B-cell lymphoma.

Rapid Progress Made With Late-Line Therapies in Metastatic Urothelial Cancer

August 6th 2020

Praful K. Ravi, MD, discusses the emergence of immunotherapies, FGFR inhibitors, and antibody-drug conjugates and how they dramatically evolved the metastatic urothelial cancer treatment paradigm.

Savolitinib Showcases Encouraging Efficacy in MET-Driven Papillary RCC

August 5th 2020

Savolitinib demonstrated encouraging efficacy and an improved safety profile over sunitinib in patients with MET-driven papillary renal cell carcinoma.

Expert Outlines Opportunities With Osimertinib in EGFR-Mutant NSCLC

August 5th 2020

Elaine Shum, MD, sheds light on osimertinib as the standard of care in the frontline treatment of patients with EGFR-mutant non–small cell lung cancer, which may be on its way to becoming a key player in the adjuvant setting and a promising option to include with novel combinations.

Adding Celecoxib to FOLFOX Does Not Demonstrate DFS Benefit in Colon Cancer

August 4th 2020

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the addition of celecoxib to standard chemotherapy, stating that it did not significantly improve disease-free survival or overall survival in patients with colon cancer.

Lenz Lends Insight on Therapeutic Approaches Shaking Up Third-Line CRC Treatment

August 3rd 2020

Heinz-Josef Lenz, MD, FACP, discusses third-line treatment approaches that are generating excitement in colorectal cancer.

El-Khoueiry Elucidates Recent Updates in the Rapidly Evolving HCC Treatment Paradigm

July 31st 2020

Anthony B. El-Khoueiry, MD, discusses the evolution of HCC treatment, paradigm-shifting trials, and where future research is headed.

Monk Magnifies Emerging Approaches Making Headway in Cervical Cancer Management

July 29th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses key updates in cervical cancer treatment, exciting ongoing research efforts, and emerging approaches that are shaking up the treatment paradigm.

Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma

July 29th 2020

R. Lor Randall, MD, FACS, discusses preoperative radiotherapy and how it has become a standard of care for patients with soft tissue sarcoma of the extremities; however, postoperative radiation still plays a role in the paradigm, especially when wound risks are considered to be precarious.

Nivolumab/Ipilimumab Shows Intriguing Clinical Activity in Metastatic Sarcomas

July 28th 2020

Gary K. Schwartz, MD, discusses the clinical findings with the combination of nivolumab and ipilimumab in patients with dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma.

Shammo Previews the Potential of Pevonedistat Combo in High-Risk MDS

July 23rd 2020

Jamile M. Shammo, MD, discusses the current treatment landscape of high-risk MDS recent data with the investigational small molecule inhibitor of the NEDD8-activating enzyme pevonedistat, and ongoing research efforts in the space.

Shore Speaks to Updates Showcasing Benefits, Safety of Darolutamide in Nonmetastatic CRPC

July 23rd 2020

Neal Shore, MD, discusses the significantly improved overall survival in patients with nonmetastatic castration-resistant prostate cancer who received darolutamide.

Litton Talks Talazoparib in BRCA1/2+ Advanced Breast Cancer

July 21st 2020

Jennifer Litton, MD, discusses findings from the phase 3 EMBRACA trial on talazoparib in patients with advanced BRCA1/2-positive breast cancer.

Ahn Expands on Advances Made With Actionable Alterations in CRC

July 17th 2020

Daniel H. Ahn, DO, discusses the slew of actionable alterations that have emerged in colorectal cancer in recent years, including targeted therapies that are boosting survival outcomes.

Bekaii-Saab Breaks Down Approach for Navigating Among Available Options in HCC

July 17th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the rapidly changing hepatocellular carcinoma treatment landscape and shares advice on how he navigates among the available options available for these patients.

Kundranda Covers Key Trials Generating Excitement in Pancreatic Cancer Paradigm

July 16th 2020

Madappa Kundranda, MD, PhD, discusses the significance of the NAPOLI-1 and NAPOLI-3 trials in pancreatic cancer, other exciting ongoing research efforts, and key challenges remaining in the space.

Sternberg Showcases Promising PROSPER Data With Enzalutamide in Nonmetastatic CRPC

July 16th 2020

Cora N. Sternberg, MD, discusses the data seen with enzalutamide in nonmetastatic castration-resistant prostate cancer, the updated survival results from the phase 3 PROSPER trial, and how she chooses among the agents available in the space.

Phase 3 Data With Eprenetapopt Plus Azacitidine Anticipated in High-Risk MDS/AML

July 14th 2020

David Sallman, MD, discusses the combination of eprenetapopt and azacitidine, a new standard of care for patients with myelodysplastic syndromes with a susceptible TP53 mutation.

Yoon Highlights Potential Benefit With Second-Line Pembrolizumab, Followed by Subsequent Therapy, in Advanced Gastric/GEJ Cancer

July 14th 2020

Harry H. Yoon, MD, discusses how second-line pembrolizumab, followed by any subsequent therapy is associated with longer overall survival in patients with advanced gastric/gastroesophageal junction cancer.

Shore Shares Promise of Relugolix for T-Suppression in Advanced Prostate Cancer

July 13th 2020

Neal D. Shore, MD, FACS, discusses the pivotal HERO trial, the promising safety data observed with relugolix, and the next steps for the agent in advanced prostate cancer.